D.A. Davidson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.29M Sell
5,139
-112
-2% -$52.2K 0.01% 657
2025
Q4
$2.38M Buy
5,251
+154
+3% +$66.4K 0.01% 612
2025
Q3
$2M Buy
5,097
+241
+5% +$101K 0.01% 645
2025
Q2
$2.16M Buy
4,856
+51
+1% +$23.5K 0.02% 588
2025
Q1
$2.33M Sell
4,805
-349
-7% -$163K 0.02% 525
2024
Q4
$2.08M Sell
5,154
-321
-6% -$149K 0.02% 553
2024
Q3
$2.55M Buy
5,475
+611
+13% +$294K 0.02% 496
2024
Q2
$2.28M Sell
4,864
-22
-0.5% -$9.55K 0.02% 501
2024
Q1
$2.04M Buy
4,886
+2,427
+99% +$1.03M 0.02% 529
2023
Q4
$1M Sell
2,459
-904
-27% -$334K 0.01% 716
2023
Q3
$1.17M Buy
3,363
+110
+3% +$38.5K 0.01% 630
2023
Q2
$1.14M Sell
3,253
-521
-14% -$176K 0.01% 649
2023
Q1
$1.19M Sell
3,774
-567
-13% -$170K 0.01% 617
2022
Q4
$1.25M Buy
4,341
+2,240
+107% +$683K 0.01% 564
2022
Q3
$608K Sell
2,101
-141
-6% -$40.6K 0.01% 751
2022
Q2
$632K Buy
2,242
+61
+3% +$16.3K 0.01% 746
2022
Q1
$569K Buy
2,181
+948
+77% +$225K 0.01% 841
2021
Q4
$271K Sell
1,233
-3
-0.2% -$583 ﹤0.01% 1083
2021
Q3
$224K Buy
+1,236
New +$241K ﹤0.01% 1117
2021
Q2
Sell
-932
Closed -$200K 1218
2021
Q1
$200K Buy
+932
New +$205K ﹤0.01% 1095
2020
Q4
Sell
-841
Closed -$229K 1041
2020
Q3
$229K Buy
841
+70
+9% +$19.3K ﹤0.01% 834
2020
Q2
$224K Buy
+771
New +$209K ﹤0.01% 829
2019
Q2
Sell
-21,676
Closed -$3.99M 1150
2019
Q1
$3.99M Sell
21,676
-624
-3% -$115K 0.07% 222
2018
Q4
$3.69M Sell
22,300
-233
-1% -$40.4K 0.07% 217
2018
Q3
$4.34M Sell
22,533
-206
-0.9% -$36.7K 0.08% 213
2018
Q2
$3.87M Sell
22,739
-672
-3% -$104K 0.08% 221
2018
Q1
$3.82M Sell
23,411
-301
-1% -$49.2K 0.08% 210
2017
Q4
$3.55M Sell
23,712
-1,326
-5% -$196K 0.07% 217
2017
Q3
$3.81M Buy
25,038
+133
+0.5% +$20K 0.07% 233
2017
Q2
$3.21M Buy
24,905
+447
+2% +$53.8K 0.07% 219
2017
Q1
$2.67M Sell
24,458
-640
-3% -$56.3K 0.06% 239
2016
Q4
$1.85M Buy
25,098
+9,058
+56% +$737K 0.04% 347
2016
Q3
$1.4M Buy
16,040
+25
+0.2% +$2.36K 0.03% 386
2016
Q2
$1.38M Buy
16,015
+337
+2% +$29.1K 0.04% 343
2016
Q1
$1.25M Buy
15,678
+738
+5% +$66.8K 0.04% 363
2015
Q4
$1.88M Sell
14,940
-61
-0.4% -$7.36K 0.06% 286
2015
Q3
$1.56M Buy
15,001
+134
+0.9% +$17.2K 0.05% 308
2015
Q2
$1.83M Buy
14,867
+752
+5% +$94.8K 0.06% 289
2015
Q1
$1.66M Sell
14,115
-1,254
-8% -$150K 0.05% 303
2014
Q4
$1.82M Sell
15,369
-4,572
-23% -$515K 0.06% 291
2014
Q3
$2.24M Sell
19,941
-120
-0.6% -$11.4K 0.08% 252
2014
Q2
$1.9M Buy
20,061
+863
+4% +$60.5K 0.06% 286
2014
Q1
$1.36M Buy
19,198
+2,677
+16% +$212K 0.05% 331
2013
Q4
$1.23M Buy
16,521
+5,284
+47% +$368K 0.05% 344
2013
Q3
$851K Buy
11,237
+852
+8% +$67.8K 0.04% 386
2013
Q2
$829K Buy
+10,385
New +$765K 0.04% 367

Other funds holding VRTX

D.A. Davidson & Co's VRTX Position: Q1 2026 in Review

D.A. Davidson & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q1 2026, selling an estimated $52.2K and leaving 5,139 shares worth $2.29M. The position accounts for 0.01% of the portfolio, ranked #657.

D.A. Davidson & Co first reported a position in VRTX in Q2 2013 and has held it in 46 quarters since. The position peaked at $4.34M in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • D.A. Davidson & Co held 5,139 shares of Vertex Pharmaceuticals worth $2.29M as of Q1 2026.
  • D.A. Davidson & Co sold 112 Vertex Pharmaceuticals shares in Q1 2026, an estimated $52.2K.
  • Vertex Pharmaceuticals made up 0.01% of D.A. Davidson & Co's portfolio in Q1 2026, its #657 holding.
  • D.A. Davidson & Co first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
  • D.A. Davidson & Co's Vertex Pharmaceuticals position peaked at $4.34M in Q3 2018.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.